Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
Lustgarten DE, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer C, Inghilleri S, Stella G, Albelda SM. Lustgarten DE, et al. Among authors: albelda sm. J Thorac Oncol. 2013 Apr;8(4):469-77. doi: 10.1097/JTO.0b013e318283da3e. J Thorac Oncol. 2013. PMID: 23486267 Free PMC article.
Cytokine gene therapy for malignant pleural mesothelioma.
Vachani A, Sterman DH, Albelda SM. Vachani A, et al. Among authors: albelda sm. J Thorac Oncol. 2007 Apr;2(4):265-7. doi: 10.1097/01.JTO.0000263706.23579.35. J Thorac Oncol. 2007. PMID: 17409795 Free article. Review. No abstract available.
Gene therapy for mesothelioma.
Vachani A, Moon E, Albelda SM. Vachani A, et al. Among authors: albelda sm. Curr Treat Options Oncol. 2011 Jun;12(2):173-80. doi: 10.1007/s11864-011-0153-5. Curr Treat Options Oncol. 2011. PMID: 21519819 Review.
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.
Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz SI, Sun J, Heitjan DF, Hwang WT, Litzky L, Yearley JH, Tan KS, Papasavvas E, Kennedy P, Montaner LJ, Cengel KA, Simone CB 2nd, Culligan M, Langer CJ, Albelda SM. Sterman DH, et al. Among authors: albelda sm. Clin Cancer Res. 2016 Aug 1;22(15):3791-800. doi: 10.1158/1078-0432.CCR-15-2133. Epub 2016 Mar 11. Clin Cancer Res. 2016. PMID: 26968202 Free PMC article. Clinical Trial.
Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy.
Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P, Amin KM, Litzky LA, Wilson JM, Kaiser LR, Albelda SM. Sterman DH, et al. Among authors: albelda sm. Clin Cancer Res. 2005 Oct 15;11(20):7444-53. doi: 10.1158/1078-0432.CCR-05-0405. Clin Cancer Res. 2005. PMID: 16243818 Clinical Trial.
Gene therapy for mesothelioma and lung cancer.
Vachani A, Moon E, Wakeam E, Albelda SM. Vachani A, et al. Among authors: albelda sm. Am J Respir Cell Mol Biol. 2010 Apr;42(4):385-93. doi: 10.1165/rcmb.2010-0026RT. Epub 2010 Feb 16. Am J Respir Cell Mol Biol. 2010. PMID: 20160042 Review.
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Thompson JC, Hwang WT, Davis C, Deshpande C, Jeffries S, Rajpurohit Y, Krishna V, Smirnov D, Verona R, Lorenzi MV, Langer CJ, Albelda SM. Thompson JC, et al. Among authors: albelda sm. Lung Cancer. 2020 Jan;139:1-8. doi: 10.1016/j.lungcan.2019.10.012. Epub 2019 Oct 18. Lung Cancer. 2020. PMID: 31683225 Free PMC article.
359 results